Royalty Report: Drugs, Biotechnology, Pharmaceuticals – Collection: 1100


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 7


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7

Primary Industries

  • Drugs
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic
  • Personal Care Products
  • Hair loss
  • Psoriasis
  • Disease
  • cardiac
  • Cancer

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 1100

License Grant
The Licensee entered into a License Agreement with the Licensor for the use of a patented protein expression system for the production of EGF epidermal growth factor, a peptide growth factor expressed in normal and diseased tissues that stimulates proliferation and alters cell differentiation in the pancreas and other organs for diabetes regenerative therapies.
Field of Use
The field of use relates to the medical industry.

IPSCIO Record ID: 802

License Grant
Subject to Canadian Licensor's right to acquire a co-exclusive interest as provided in this Agreement, Licensor grants to the Company an exclusive, royalty-bearing, worldwide license, with the right to grant sublicenses to the Company Sublicensees, under the Cell Technology and Patent Rights to make, have made, use, have used, sell, have sold, and manipulate Products in the Field and to perform the Services in the Field.
License Property
Cell Technology shall mean all know-how, data, biological materials, inventions and other proprietary information and technology relating to the manufacture, sale, use or manipulation of Cells within the Field provided to the Company prior to the Effective Date.

Cells shall mean in vitro generated, growth factor responsive neural stem cells to the extent claimed in the Patent Rights and shall include all progeny and derivatives of such stem cells (including Progenitor Cells and their progeny and Stem Cells and their progeny) and Cell shall mean one of such cells. An in vitro generated growth factor responsive neural stem cell shall include a neural stem cell, or its derivatives or progeny, which exhibits one or more of the following characteristics

(a) is dependent on the presence of a growth factor for survival and viability, or (b) proliferates or differentiates due to the presence of a growth factor, whether alone or in combination with another biologically active molecule; and

An EGF-responsive neuronal stem cell includes
a neuronal stem cell, or its derivatives or progeny, which exhibits one or more of the following characteristics

(a) is dependent on the presence of EGF for survival and viability, or (b) proliferates or differentiates due to the presence of EGF, whether alone or in combination with another biologically active molecule all to the extent claimed or allowed under the Patent Rights.

Product shall mean any product utilizing the Cells and the manufacture, use, or sale of which, but for the license granted to the Company hereunder, would infringe any claim of the Patent

Services shall mean any use of the Cells or the Cell Technology to perform a service for a third party for compensation, where such use would, but for the license granted to the Company hereunder, infringe any claim of the Patent Rights.

Field of Use
Field shall mean the use of Cells for Transplantation only, including, without limitation

(a) for Cell Replacement Therapy; (b) for the purposes of Transplantation anywhere in the human body for the treatment or prevention of human disease, injury, or disorder; (c) for augmenting the function of endogenous cells by Transplantation or Cell Replacement Therapy; and (d) for the purposes of transplantation therapy in general (e.g., Transplantation of the Cells for delivery of one or more Agents).

IPSCIO Record ID: 28991

License Grant
Licensor grants an exclusive license for the Licensed Technology in the Field, including, without limitation, the patents and patent applications with the right to grant sublicenses, as well as the right of its sublicensees to grant further sublicenses, to make, have made, use, distribute and sell Licensed Products in the Field using the Licensed Technology covered by the Licensed Patent Rights throughout the Territory.
License Property
PTH technologies useful in the treatment of psoriasis and hair loss.

U.S. Patent No. 5,527,772, 5,840,690, 6,066,618

IPSCIO Record ID: 5995

License Grant
Pursuant to this Agreement Licensee now has worldwide, exclusive License rights to the U.S. and foreign patents and patent applications for all topical uses of PTH(1-34) for the treatment of hyperproliferative skin disorders including psoriasis.
Field of Use
Field of use relates to the medical industry.

IPSCIO Record ID: 25941

License Grant
The Agreement, dated as of July 25, 2003,  for sales of Increlex, a DNA-derived recombinant human insulin-like growth factor-1 (rhIGF-1), and of any drug that combines rhIGF-1 and IGF binding protein-3.
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 7028

License Grant
The Company Licensed from a certain Foundation, a related party, the Stromal Cell technology for potential therapeutic use in the regrowth of damaged cardiac cells after a heart attack.
License Property
The Company has sub-Licensed the StromaCel Technology to the sublicensee, but the Company will remain responsible for all costs associated with patent prosecution for the StromaCel Technology.

In the event of bankruptcy, the rights to the Technology granted by the License revert to the Foundation.

Stromal cells are key components of tissues and provide critical cytokines and growth factors as well as the cellular microenvironment for normal homeostasis. A cytokine is a small protein released by cells that affects the interactions and communications between cells and the behavior of cells. A growth factor is a naturally occurring substance capable of stimulating cellular growth, proliferation and differentiation. Homeostasis is a self-regulating process by which a biological system maintains stability while adjusting to changing conditions. Stromal cells provide a niche proliferation environment for stem cells.

Field of Use
The rights granted apply to the medical industry relating to stem cell therapeutics.

IPSCIO Record ID: 29334

License Grant
Parties hereto shall work together to complete the research and development of anti-tumor drug AL6802 (a chemical compound that covered by the pending U.S. patent and the future PCT patent application mentioned above) in China (and other countries and regions outside China), and finally have AL6802 Pharmaceutical registration and invention patent granted in China mainland and carry out relevant commercial development in China and other countries and regions outside China. The period for the royalties shall be the patent protection period of AL6802 in China.  Al-6802 belongs to a series of small molecules developed that have very potent activity at in vitro human cancer cell proliferation assay and in vivo human cancer cell A431 xenograft model.
Field of Use
This compound is targeting epidermal growth factor receptor (EGFR) for cancer treatment.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.